**Supplementary Table 1. Baseline procedural and laboratory findings**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables, n (%)** | **Reduced EF(n = 62 pts)** | **Mid-range EF(n = 76 pts)** | **Preserved EF(n = 764 pts)** | **p value** |
| **Coronary artery disease (%)** | **48 (77.4)** | **57 (75.0)** | **434 (56.8)** | **<0.001** |
|  Prior CABG (%) | 7 (11.2) | 4 (5.2) | 28 (3.6) | 0.021 |
|  Prior PCI (%) | 20 (32.2) | 23 (30.2) | 171 (22.3) | 0.080 |
|  PCI during PTA (%) | 23 (37.0) | 27 (35.5) | 186 (24.3) | **0.014** |
| **Routine coronary angiography (%)** | 52 (83.8) | 67 (88.1) | 666 (87.1) | 0.723 |
| Affected vessels |  |  |  |  |
|  LM (%) | 11 (17.7) | 14 (18.4) | 52 (6.8) | **<0.001** |
|  LAD (%) | 30 (48.3) | 37 (48.6) | 260 (34.0) | **0.005** |
|  LCX (%) | 30 (48.3) | 29 (38.1) | 235 (30.7) | **0.010** |
|  RCA (%) | 25 (40.3) | 39 (51.3) | 232 (30.3) | **<0.001** |
| Multi-vessel disease (%) | 31 (50.0) | 40 (52.6) | 246 (32.1) | **<0.001** |
|  |  |  |  |  |
| **Limb characteristic** |  |  |  |  |
| Both limbs | 23 (37.0) | 14 (18.4) | 150 (19.6) | 0.004 |
| Right | 42 (67.7) | 48 (63.1) | 474 (62.0) | 0.667 |
| Left | 44 (70.9) | 45 (59.2) | 466 (60.9) | 0.273 |
| Affected vessel |  |  |  |  |
|  Distal aorta | 3 (4.8) | 1 (1.3) | 14 (1.8) | 0.202 |
|  Iliac | 14 (22.5) | 28 (36.8) | 193 (25.2) | 0.073 |
|  Femoral | 15 (24.1) | 26 (34.2) | 215 (28.1) | 0.401 |
|  Popliteal | 14 (22.5) | 8 (10.5) | 78 (10.2) | 0.012 |
|  Tibioperoneal trunk | 3 (4.8) | 2 (2.6) | 12 (1.5) | 0.099 |
|  Anterior tibial artery | 34 (54.8) | 35 (46) | 425 (55.6) | 0.278 |
|  Posterior tibial artery | 29 (46.7) | 26 (34.2) | 325 (42.5) | 0.279 |
|  Peroneal artery | 16 (25.8) | 18 (23.6) | 156 (20.4) | 0.511 |
|  |  |  |  |  |
| **Laboratory findings** |  |  |  |  |
| Hemoglobin | 11.0 ± 2.0 | 11.7 ± 2.5 | 11.5 ± 2.0 | 0.271 |
| Fasting blood sugar | 154 ± 82.4 | 152.7 ± 70.0 | 149.9 ± 76.1 | 0.595 |
| HbA1c | 7.0 ± 1.9 | 6.7 ± 1.2 | 7.2 ± 3.2 | 0.098 |
| Total cholesterol | 136.5 ± 34.4 | 156.8 ± 42.5 | 145.1 ± 53.4 | 0.429 |
| Triglyceride | 117.6 ± 64.5 | 127.7 ± 55.5 | 125.4 ± 91.6 | 0.519 |
| High-density lipoprotein cholesterol | 36.5 ± 13.7 | 37.2 ± 12.2 | 37.3 ± 14.3 | 0.856 |
| Low-density lipoprotein cholesterol | 83.6 ± 28.2 | 95.0 ± 36.7 | 85.8 ± 34.7 | 0.230 |
| High-sensitivity C-reactive protein | 44.8 ± 72.6 | 22.9 ± 35.2 | 19.8 ± 41.2 | 0.154 |
| Creatinine | 3.16 ± 2.83 | 2.86 ± 3.59 | 2.01 ± 2.51 | **<0.001** |
|  |  |  |  |  |
|  |  |  |  |  |

CABG, coronary artery bypass grafting; EF, ejection fraction; ICU, intensive care unit; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty; RCA, right coronary artery

**Supplementary Table 2. In-hospital complications and major clinical outcomes at 5 years**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables, n (%)** | **Reduced EF(n = 62 pts)** | **Mid-range EF(n = 76 pts)** | **Preserved EF(n = 764 pts)** | **p value** |
| **Procedural and in-hospital complications** |  |  |  |  |
| Pseudoaneurysms | 3 (4.8) | 1 (1.3) | 4 (0.5) | 0.009 |
| Hematoma (access-site complications) | 8 (12.9) | 5 (6.5) | 80 (10.4) | 0.446 |
|  Minor | 3 (4.8) | 4 (5.2) | 55 (7.1) | 0.659 |
|  Major | 5 (8.0) | 1 (1.3) | 30 (3.9) | 0.139 |
| Gastrointestinal bleeding | 3 (4.8) | 0 (0.0) | 7 (0.9) | 0.036 |
| Retroperitoneal bleeding | 1 (1.6) | 1 (1.3) | 4 (0.5) | 0.230 |
| Transfusion | 31 (50.0) | 28 (36.8) | 253 (33.1) | 0.025 |
|  Volume, pints | 6.1 ± 11.9 | 4.0 ± 7.3 | 4.6 ± 7.8 | 0.957 |
| Congestive heart failure | 2 (3.2) | 0 (0.0) | 2 (0.2) | 0.033 |
| Ischemic stroke | 1 (1.6) | 0 (0.0) | 5 (0.6) | 0.411 |
| Hemorrhagic stroke | 0 (0.0) | 0 (0.0) | 1 (0.1) | >0.999 |
| Stay in hospital, days | 44.2 ± 42.6 | 39.5 ± 72.5 | 36.0 ± 45.2 | 0.149 |
| Stay in ICU, days | 2.9 ± 7.7 | 0.9 ± 2.4 | 0.7 ± 3.6 | **<0.001** |
| **Clinical outcomes at 30 days** |  |  |  |  |
| Total death | 3 (4.8) | 2 (2.6) | 13 (1.7) | 0.141 |
| Myocardial infarction | 0 (0.0) | 0 (0.0) | 2 (0.2) | >0.999 |
| Stroke | 0 (0.0) | 1 (1.3) | 3 (0.3) | 0.486 |
| Major adverse cerebral and cardiovascular events | 3 (4.8) | 3 (3.9) | 18 (2.3) | 0.238 |
| Repeat PTA | 1 (1.6) | 0 (0.0) | 7 (0.9) | 0.525 |
|  Target lesion revascularization | 0 (0.0) | 0 (0.0) | 5 (0.6) | >0.999 |
|  Target extremity revascularization: TER | 1 (1.6) | 0 (0.0) | 6 (0.7) | 0.470 |
|  Non-TER | 0 (0.0) | 0 (0.0) | 1 (0.1) | >0.999 |
| Target extremity surgery | 3 (4.8) | 5 (6.5) | 76 (9.9) | 0.286 |
|  Above the knee amputation | 0 (0.0) | 0 (0.0) | 3 (0.3) | >0.999 |
|  Above the ankle amputation | 2 (3.2) | 1 (1.3) | 10 (1.3) | 0.298 |
|  Below the ankle amputation | 3 (4.8) | 4 (5.2) | 68 (8.9) | 0.324 |
| Major adverse limb events | 4 (6.4) | 5 (6.5) | 82 (10.7) | 0.319 |
|  |  |  |  |  |
| **Clinical outcomes up to 5 years** |  |  |  |  |
| Total death | **12 (19.7)** | **10 (13.8)** | **59 (8.9)** | **0.001** |
| Myocardial infarction | 2 (3.8) | 1 (1.4) | 5 (0.9) | 0.035 |
| PCI | 5 (9.6) | 6 (8.7) | 37 (5.7) | 0.107 |
| Stroke | 1 (2.0) | 3 (4.2) | 24 (4.0) | 0.730 |
| Major adverse cerebral and cardiovascular events | 14 (22.9) | 18 (24.4) | 108 (16.1) | 0.011 |
| Repeat PTA | 16 (29.8) | 16 (23.9) | 170 (25.0) | 0.524 |
|  Target lesion revascularization | 9 (17.3) | 12 (17.7) | 127 (18.6) | 0.811 |
|  Target extremity revascularization: TER | 13 (24.1) | 14 (21.2) | 141 (20.6) | 0.516 |
|  Non-TER | 5 (10.4) | 6 (10.2) | 60 (9.3) | 0.882 |
| Target extremity surgery | 15 (26.5) | 15 (21.3) | 118 (16.4) | 0.021 |
|  Above the knee amputation | 0 (0.0) | 0 (0.0) | 9 (1.3) | 0.241 |
|  Above the ankle amputation | 3 (5.3) | 7 (9.7) | 31 (4.3) | 0.210 |
|  Below the ankle amputation | 15 (26.5) | 15 (21.3) | 118 (16.4) | 0.021 |
| Major adverse limb events | 25 (44.3) | 24 (34.1) | 244 (34.6) | 0.109 |

EF, ejection fraction; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty

Data are shown as mean ± SD or number (percentage).